TIM-3 as a therapeutic target in human inflammatory diseases
- 31 July 2007
- journal article
- review article
- Published by Taylor & Francis in Expert Opinion on Therapeutic Targets
- Vol. 11 (8) , 1005-1009
Abstract
T-cell immunoglobulin- and mucin-domain-containing molecule-3 (Tim-3) was the first, and is presently the only, surface molecule that can specifically identify TH1 cells in both mice and humans. Engagement of Tim-3 by its ligand galectin-9 negatively regulates IFN-γ secretion and influences the ability to induce T cell tolerance in both mice and man. Numerous studies have demonstrated that Tim-3 influences autoimmune diseases, including diabetes and multiple sclerosis, and its role in other inflammatory diseases including allergies and cancer is beginning to become clear.Keywords
This publication has 38 references indexed in Scilit:
- Antibodies to T-cell Ig and mucin domain-containing proteins (Tim)-1 and -3 suppress the induction and progression of murine allergic conjunctivitisBiochemical and Biophysical Research Communications, 2007
- A highly conserved tyrosine of Tim-3 is phosphorylated upon stimulation by its ligand galectin-9Biochemical and Biophysical Research Communications, 2006
- Dysregulated T cell expression of TIM3 in multiple sclerosisJournal of Experimental Medicine, 2006
- Anti-IL-23 therapy inhibits multiple inflammatory pathways and ameliorates autoimmune encephalomyelitisJournal of Clinical Investigation, 2006
- Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cellsNature, 2006
- Adoptive immunotherapy for cancer: building on successNature Reviews Immunology, 2006
- Molecular variations in Th1-specific cell surface gene Tim-3Experimental & Molecular Medicine, 2004
- Possible role of galectin‐9 in cell aggregation and apoptosis of human melanoma cell lines and its clinical significanceInternational Journal of Cancer, 2002
- T-cell subsets (Th1 versus Th2)Annals of Allergy, Asthma & Immunology, 2000
- Th1-Th2: Reliable paradigm or dangerous dogma?Immunology Today, 1997